Who Owns Nuvaxovid?

Novavax operates under a comprehensive Environmental, Social, and Governance (ESG) framework focused on four strategic pillars: improving global health, ensuring access to vaccines, maintaining high governance standards, and mitigating environmental impact. The company's sustainability approach is integrated into its business operations and corporate strategy.

Environmental Commitment: Novavax aims to operate in an environmentally sustainable manner that reduces its environmental impact across its manufacturing and research operations. The company focuses on responsible resource management, waste reduction, and energy efficiency in its biomanufacturing facilities. Novavax's environmental initiatives include optimizing manufacturing processes to reduce water and energy consumption, implementing sustainable waste management practices, and evaluating the environmental footprint of its supply chain operations.

Global Health Access: A core component of Novavax's sustainability strategy is maximizing access to vaccines and improving global health outcomes. The company works to ensure equitable access to Nuvaxovid through partnerships with global health organizations, tiered pricing for different markets, and technology transfer agreements with international manufacturers. Novavax's partnership with Sanofi significantly expands global access to Nuvaxovid, particularly in low and middle-income countries where vaccine access has historically been limited.

Ethical Research and Development: Novavax maintains high ethical standards in its clinical research and development programs. The company conducts rigorous clinical trials following Good Clinical Practice guidelines, ensures informed consent from trial participants, and maintains transparency in reporting clinical trial results. Novavax's protein subunit technology platform is developed with attention to safety, efficacy, and ethical considerations in vaccine development.

Governance and Compliance: Novavax operates under strong corporate governance principles with oversight from an independent Board of Directors. The company maintains compliance with regulatory requirements across all markets where Nuvaxovid is sold, including FDA regulations, European Medicines Agency standards, and other international regulatory frameworks. Novavax's governance structure includes risk management, compliance programs, and ethical business practices appropriate for a publicly traded biotechnology company.

Nuvaxovid and Novavax have received recognition primarily for scientific innovation and regulatory achievements.

FDA BLA Approval (May 19, 2025): The FDA approval of Nuvaxovid's biologics license application marked a significant regulatory achievement, making Nuvaxovid the first protein subunit COVID-19 vaccine to receive full FDA approval.

2025-2026 Formula Approval (August 27, 2025): The FDA approved the 2025-2026 formula of Nuvaxovid, the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season.

Scientific Recognition: Novavax's recombinant nanoparticle technology and Matrix-M adjuvant platform have been recognized for their innovation in vaccine development. The 90.4 percent efficacy demonstrated in the PREVENT-19 Phase 3 trial established the scientific validity of protein subunit vaccines for COVID-19.

Sanofi Partnership Achievement: The 2023 co-commercialization agreement with Sanofi, valued at approximately $1.2 billion upfront plus ongoing royalties, represented industry recognition of Nuvaxovid's commercial potential. The November 2025 completion of the U.S. marketing authorization transfer to Sanofi further validated this partnership.

Pfizer Matrix-M License (January 2026): The license agreement with Pfizer, granting rights to use Matrix-M adjuvant in up to two disease areas for $30 million upfront, represented the first external licensing of Novavax's adjuvant technology to a major pharmaceutical company.

Regulatory Authorization Delays: Novavax experienced delays in obtaining regulatory authorization for Nuvaxovid compared to mRNA vaccine manufacturers. The FDA granted emergency use authorization in July 2022, later than anticipated, which limited Nuvaxovid's market share during the peak COVID-19 vaccination period. These delays were primarily due to manufacturing facility inspections and data review processes.

Manufacturing Challenges: Novavax faced manufacturing challenges early in Nuvaxovid's development, including issues with scaling up production of the recombinant nanoparticle antigen and Matrix-M adjuvant. These challenges contributed to delays in meeting supply commitments.

Myocarditis and Pericarditis Risk: Like other COVID-19 vaccines, Nuvaxovid carries an identified risk of myocarditis and pericarditis, particularly in young male recipients. The FDA labeling includes warnings about these risks, and the CDC has published clinical considerations for vaccination of individuals with a history of myocarditis or pericarditis.

Market Competition Challenges: Nuvaxovid has faced significant market challenges competing with established mRNA vaccines from Pfizer-BioNTech and Moderna. The vaccine's later market entry and the dominance of mRNA vaccines created commercial difficulties for Novavax, leading to the Sanofi partnership and eventual marketing authorization transfer.

EUA Revocation (August 27, 2025): The FDA revoked the Emergency Use Authorizations for previous Fall 2024 COVID-19 vaccines, including earlier Nuvaxovid formulations, when it approved the 2025-2026 formula. This was a standard regulatory transition rather than a safety-related recall.

Allergic Reaction Concerns: Nuvaxovid carries contraindications for individuals with known severe allergic reactions to any component of the vaccine, including the Matrix-M adjuvant. The saponin-based adjuvant presents different allergic reaction profiles compared to mRNA vaccine components.